Facebook
X
LinkedIn
Forward
Biosimilars in Osteoporosis Care: What Clinicians Need to Know
The session will explore emerging clinical evidence, practical approaches for integrating biosimilars into individualized treatment plans, and key considerations related to safety, efficacy, and cost-effectiveness. Designed for a multidisciplinary audience—including primary care physicians, endocrinologists, rheumatologists, nurse practitioners, and other healthcare professionals involved in osteoporosis management—the webinar will provide timely, evidence-based insights relevant to real-world clinical practice.
Participants will gain actionable guidance to support informed decision-making around biosimilar adoption and to enhance patient care outcomes. This program is committed to delivering superior quality, scientifically rigorous, independent, and impartial education aimed at improving the knowledge and competence of healthcare providers and supporting excellence in the prevention, diagnosis, and treatment of osteoporosis.
Target Audience
This continuing education activity is intended for use by health professionals who participate in the care of patients at risk for or suffering from osteoporosis, in the areas of primary care, endocrinology, geriatrics, gynecology, internal, obstetrics, orthopedics, osteopathy, pediatrics, physiatry, radiology, rheumatology and physical therapy.
This includes physicians, nurse practitioners, registered nurses, pharmacists, physician assistants, technologists, researchers, public health professionals and health educators with an interest in osteoporosis and bone health.
Learning Objectives
1. Describe the biosimilar approval pathway and key considerations for clinical use in osteoporosis care.
2. Identify appropriate patients for initiation of biosimilar therapy.
3. Compare strategies for transitioning from reference biologics to biosimilars.
4. Apply approaches for payer and formulary navigation.
5. Use patient-centered communication strategies to support shared decision-making.
Course summary
Name of Individual | Individual's Role(s) in Activity | Name of Ineligible Company(s) | Nature of Relationship(s) |
Amy Mitchell, MSN, FNP-C | Nurse Planner; Accredited Provider Program Director; content reviewer | N/A | N/A |
Ami Patel | BHOF Staff, Vice President of Science & Education | N/A | N/A |
Stuart L. Silverman, MD, FACP, FACR | Faculty; content developer | Sandoz | Advisory |
Disclosure of Financial Relationships
All individuals in a position to control content have disclosed relevant financial relationships with ineligible companies within the past 24 months. All relevant financial relationships have been reviewed and mitigated.
Acknowledgment of Commercial Support
This activity is made possible by support from Sandoz.
UPDATED: August 21, 2026
Criteria for Successful Completion
To receive credit/contact hours, participants must attend at least 50 minutes of the 60-minute live webinar and complete the post-activity evaluation.
Accreditation Statement
For Physicians: The Bone Health and Osteoporosis Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Bone Health and Osteoporosis Foundation designates this internet live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™.
For Nurses and Nurse Practitioners: The Bone Health and Osteoporosis Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. The Bone Health and Osteoporosis Foundation designates this activity for 1.0 continuing nursing education contact hours.
For all other members of the Healthcare Team: A certificate of attendance will be provided to all other health care professionals requesting credits in accordance with state licensing boards, specialty societies, or other professional associations.
Disclosure of Financial Relationships
All individuals in a position to control content have disclosed relevant financial relationships with ineligible companies within the past 24 months. All relevant financial relationships have been reviewed and mitigated.
Acknowledgment of Commercial Support
This activity is made possible by support from Sandoz.
UPDATED: August 21, 2026